Just a quick note on a topic that keeps catching my attention: China. Three interesting things have come up in the last month:
- Organogenesis signs a distribution deal with China’s National Tissue Engineering Center, with the potential to expand into manufacturing and joint product development activities.
- WuXi Pharmatech purchases contract organization Apptec to gain a US footprint and expertise in biologics.
- Regenerative Medicine venture capital firm Toucan Capital has two positions open that require both an advanced life science degree and fluency in Chinese – I wonder where they are looking to invest their next round of funding?
With the US dollar so low and the Chinese markets so hot, it is highly possible we see even more investment from Chinese firms in US regenerative medicine companies as we are seeing in other industries. But I wonder how much more US-based capital will make it into China?
The Regeneration Station 
Pingback: Regenerative medicine progress in regions | Stem Cell Assays